Growth hormone vs growth-hormone-releasing peptides: what each one actually does

TL;DR

• rhGH supplies the hormone; secretagogues ask the gland for it - the difference is where the intervention sits relative to the feedback loop.
• Exogenous GH bypasses feedback and suppresses your own secretion - secretagogues leave the loop closed, which also caps what they can achieve.
• rhGH's approved indications are narrow - deficiency and defined paediatric growth disorders, never anti-ageing or physique; US federal law treats off-indication distribution as a criminal offence.
• In healthy older adults, GH moved body composition but not strength or function, alongside markedly higher rates of adverse effects.
• The strongest secretagogue dataset belongs to MK-677 - two years, fat-free mass up, function not improved, fasting glucose up and insulin sensitivity down.
• No head-to-head trial exists - "same benefits, safer" is unsupported in either direction, and a research-chemical vial is a separate problem from the pharmacology.

---

Educational content, not medical advice. This article contains no doses, schedules or protocols.

The one-sentence difference: replacing the hormone versus asking the body to release it

Almost everything that follows unpacks a single distinction.

Recombinant human growth hormone (rhGH, generically somatropin) is the hormone itself, manufactured to match the 191-amino-acid human sequence and administered directly. The pituitary is not consulted. Whatever it was doing, the injected hormone is added on top of it.

Growth-hormone secretagogues are signals, not the hormone. GHRH analogues bind the GHRH receptor on the pituitary; ghrelin-receptor agonists bind a different receptor and lift the somatostatin brake. Either way, the molecule that reaches tissue is still the body's own GH, released by the body's own gland, on the body's own terms.

That single structural fact propagates into every other difference between the two categories:

If you want the biology underneath this table - what GHRH is, what somatostatin does, how the liver converts a GH pulse into IGF-1, and where each named compound sits in that chain - that is a separate article and it is the one to read first: the GH axis and GHRH peptides. This page assumes that map and does something narrower with it. It answers the comparison question, not the mechanism question.

Pulsatility - why when GH appears may matter as much as how much

This is the section that matters, and it is the one most often flattened into a slogan.

Endogenous growth hormone secretion is pulsatile. Across twenty-four hours the pituitary releases GH in a series of discrete bursts separated by intervals in which circulating GH falls to very low, often barely detectable, levels. The largest and most reliable of those bursts is associated with early slow-wave sleep. This is not incidental architecture - it is the normal operating pattern of the axis, and it is what tissue receptors are exposed to under ordinary physiology. (The sleep half of this is covered separately in the GH pulse and deep sleep.)

An injection of recombinant GH does not reproduce that. It produces a single rise and decay shaped by the pharmacokinetics of the preparation rather than by the hypothalamus. The peak is not a physiological pulse and the trough is not a physiological trough: baseline sits higher than it otherwise would, and the alternation between signal and silence - the thing the axis normally does - is substantially reduced.

Does that matter? The honest answer has two parts, and both need saying.

The mechanistic case that pattern matters is genuine. The best-characterised evidence comes from hepatic gene regulation, where pulsatile versus continuous GH exposure has been shown to drive different downstream signalling - the intracellular transducer for GH signalling responds to intermittent stimulation differently from sustained stimulation, and the resulting patterns of liver gene expression differ accordingly. This work is largely rodent, and the sexually dimorphic secretion patterns it exploits are a rodent feature; it establishes that GH pattern is a biologically real variable, not that any particular human outcome follows from it.

Secretagogues preserve feedback, and that is a genuine pharmacological difference. Because a secretagogue acts upstream, the GH it releases and the IGF-1 that follows both feed back onto the hypothalamus and pituitary - raising somatostatin tone and damping further release. The loop stays closed. With exogenous GH the loop is not merely intact-but-quiet; the added hormone actively suppresses the person's own secretion, because from the axis's point of view there is already plenty of GH present.

This is where the argument has to stop short of where the marketing takes it. Preserved feedback is a mechanistic property, and it is verifiable. "More physiological" is a reasonable description of that property. It is not, by itself, an outcome claim. A closed loop is a good reason to expect a bounded effect and a different side-effect profile; it is not evidence that any specific benefit occurs, occurs more safely, or occurs at all. The distance between "this mechanism is more like normal physiology" and "this produces better results in people" has to be crossed by comparative trials, and in healthy adults those trials have largely not been done.

Preserved feedback also has a consequence that the same marketing rarely mentions: it is precisely the mechanism that caps what a secretagogue can do. That is section five.

Recombinant GH: approved indications, and how narrow they are

Recombinant human GH is a long-established prescription medicine. Its approved indications are specific, mostly deficiency- or disease-defined, and considerably narrower than the public conversation implies. Approvals are also product-specific: individual somatropin brands carry different subsets of indications, and no single product carries all of them.

Broadly, the approved territory covers:

• Growth hormone deficiency in children - the original indication.
• Growth hormone deficiency in adults, where deficiency is established by appropriate diagnostic testing rather than by symptoms alone.
• A defined set of paediatric growth disorders, including Turner syndrome, Prader-Willi syndrome, children born small for gestational age who fail to show catch-up growth, growth failure associated with chronic kidney disease, SHOX deficiency, Noonan syndrome, and idiopathic short stature.
• Two conditions outside growth entirely, carried by specific products: short bowel syndrome, and HIV-associated wasting or cachexia.

What is not on that list is the entire reason most people search this topic. Recombinant GH is not approved for anti-ageing, athletic performance, recovery, or body composition in healthy adults. This is worth stating without softening, because it is often presented as a technicality about paperwork. It is not. It means no regulator has reviewed evidence for those uses and concluded the benefit-risk balance supports them.

In the United States the position is stronger than "unapproved". Federal law treats the distribution or possession of human growth hormone for uses other than the treatment of a disease or recognised medical condition, authorised by the FDA and pursuant to a valid prescription, as a criminal offence rather than a regulatory infraction. Growth hormone is essentially unique among non-controlled prescription drugs in carrying that specific statutory restriction. Any product marketed to healthy adults for physique or anti-ageing purposes is operating outside that framework, whatever the accompanying paperwork says.

Secretagogues: GHRH analogues versus ghrelin-receptor agonists

"Peptides" is not a regulatory category and tells you nothing about status. Within the secretagogue side there are two distinct mechanisms and at least three distinct legal situations, and conflating them is where most reader harm originates.

GHRH analogues are built on the body's own releasing hormone and act at the GHRH receptor. Ghrelin-receptor agonists (also called GH secretagogue receptor agonists, and including the older GHRP series) act at a different receptor, increase pulse amplitude, and suppress somatostatin. They are not interchangeable, and they do not have the same status.

Two things follow that are easy to miss. First, MK-677 is frequently grouped under "GH peptides" and is not a peptide at all - it is a small orally bioavailable molecule that happens to hit the same receptor. Second, the only genuine treatment approval anywhere in this class belongs to tesamorelin, for one indication, in one population. The head-to-head comparison of the GHRH analogues specifically is covered in sermorelin vs CJC-1295 vs tesamorelin.

What the evidence supports for each - and the ceiling on secretagogue effect

For recombinant GH in diagnosed deficiency, the evidence is strong and the indication is not controversial: replacing a hormone in someone who demonstrably lacks it.

For recombinant GH in healthy older adults, the picture is much less flattering than its reputation. Systematic review of the controlled trials in this population has consistently found a modest increase in lean mass and a modest decrease in fat mass, without accompanying improvement in strength or functional capacity, alongside markedly higher rates of adverse effects than placebo - fluid retention, arthralgia, carpal-tunnel-type symptoms, gynaecomastia, and impaired glucose tolerance. Larger randomised work combining GH with sex steroids in healthy older adults reported the same shape of result: body composition moved, function largely did not, and adverse events were common. This is one of the more instructive findings in the whole field, because it separates a change in a scan from a change in what a person can do.

For secretagogues, the strongest human dataset belongs to the compound with the weakest legal standing. A two-year randomised placebo-controlled trial of the oral ghrelin mimetic MK-677 - an unapproved investigational compound - in healthy older adults restored GH and IGF-1 towards levels typical of younger adults and produced a significant increase in fat-free mass. It did not produce significant improvement in strength or function, and it did increase fasting glucose and reduce insulin sensitivity. That trial is the closest thing the field has to a real answer, and its answer closely mirrors the healthy-adult recombinant GH literature: the marker moves, the composition moves somewhat, the function does not reliably follow, and glucose handling gets worse.

Tesamorelin's evidence base is real but narrow. The pivotal randomised trials demonstrated meaningful reduction in visceral adipose tissue in people with HIV-associated lipodystrophy over roughly six months, with a documented adverse-effect profile including injection-site reactions, arthralgia, peripheral oedema and glucose intolerance. That evidence supports that indication in that population. It is not evidence for body composition in healthy adults, and treating it as such is exactly the "approved for X, therefore evidence for Y" error.

Now the ceiling, which is the honest answer to do GH peptides work like HGH.

Because secretagogues act upstream of an intact feedback loop, their effect on GH and IGF-1 is bounded in a way that exogenous hormone is not. Rising GH and IGF-1 increase somatostatin tone and reduce hypothalamic drive; the GHRH receptor itself desensitises with sustained stimulation. The consequence is real but constrained elevation, with diminishing returns rather than a dose-proportional climb. A person cannot push endogenous secretion to an arbitrary level by asking harder, because the asking is what the loop regulates.

That boundedness is frequently sold as a safety feature. It may well function as one - a system that cannot be driven to arbitrary levels is a system with a narrower failure mode. But the framing "same benefits, safer" fails on both halves. Head-to-head comparative outcome trials of recombinant GH against secretagogues in healthy adults have essentially not been done. There is no dataset showing equivalent benefit, and there is no dataset showing superior safety, because the comparison that would generate either has not been run. What exists is a mechanistic argument on one side and, on the other, a body of evidence suggesting that when either route does raise IGF-1 in healthy adults, the resulting side-effect signature - particularly on glucose - looks broadly similar, because it is downstream of the same signal.

IGF-1 as the shared readout, and its limits

Both categories are monitored the same way, primarily through IGF-1. This is sensible: GH itself is pulsatile and a single measurement is close to uninterpretable, whereas IGF-1 is comparatively stable and integrates GH exposure over a longer window. It is the practical readout, and there is no better routine alternative.

It is also an imperfect one, in ways that matter for interpreting any claim built on it.

• Nutrition moves it. IGF-1 falls with energy restriction and with inadequate protein intake, independent of GH. A person changing their diet and their compound at the same time cannot attribute the result to either.
• The liver produces most of it. Hepatic impairment lowers IGF-1 regardless of pituitary function.
• It declines with age, which is why interpretation is against age- and sex-referenced ranges rather than a universal number.
• Assays are not interchangeable. Different platforms, different reference populations, different binding-protein handling. Values from two laboratories are not reliably comparable, and a change on paper can reflect a change of assay.
• Binding proteins complicate it. Most circulating IGF-1 is bound; total IGF-1 does not straightforwardly report bioavailable IGF-1.

The most important limit is conceptual rather than analytical. A moved IGF-1 is not a clinical outcome. It is a biomarker of axis activity. The healthy-adult literature above is precisely a demonstration that IGF-1 and composition can move while strength and function do not - which means a laboratory value on a report cannot substitute for evidence that anything worthwhile happened. Interpreting that value, and deciding what if anything it justifies, is clinical work.

The safety and regulatory asymmetry between the two

The two sides of this comparison are not merely differently regulated. They are differently knowable, and that asymmetry runs in both directions.

Recombinant GH is a known quantity with a known risk profile. Decades of use in defined indications have characterised its adverse effects reasonably well: fluid retention and oedema, arthralgia and joint stiffness, carpal tunnel syndrome, insulin resistance and impaired glucose tolerance, and - because the entire point of the axis is a growth signal - the standing contraindication in active malignancy. Those risks are documented, monitored, and managed within a supervised framework.

Most secretagogues are not a known quantity. For several of the compounds in the table above there are no long-term human safety data at all, because the trials that would produce them were never run or were abandoned. Absence of documented harm in a compound nobody has studied for long enough is not reassurance; it is absence of information, and it should be read as such.

And then there is the distinction that matters most in practice, which is not pharmacological at all.

The approved pharmaceutical product and the same-named research chemical are not the same thing. A vial labelled with a compound name from a research supplier and an approved medicine containing the same molecule are different products in every respect that determines what actually enters a person: different manufacturing standards, different purity and identity testing, different sterility assurance, different stability and storage validation, different labelling requirements, different regulatory oversight, and different accountability if something is wrong. Research-grade material is manufactured and sold for laboratory use, and is generally labelled as not for human consumption because that is what it is. Independent testing of this market has repeatedly found products that are underdosed, overdosed, degraded, contaminated, or not the labelled compound. Sharing a name with an approved medicine confers none of the properties that make the approved medicine what it is.

That distinction sits underneath everything else on this page. A comparison between recombinant GH and a secretagogue is a comparison of two pharmacologies. A comparison between an approved medicine dispensed through a supervised pathway and an unregulated product of unverified identity is a different comparison entirely, and the second one is not resolved by anything in the biology.

Frequently asked questions

Do GH peptides work like HGH? Not in the sense the question usually means. They act through a different point in the same system: recombinant GH supplies the hormone, secretagogues prompt the pituitary to release it. Secretagogues can raise GH and IGF-1 measurably, and in at least one long randomised trial of an unapproved investigational compound they raised IGF-1 towards younger-adult levels and increased fat-free mass. But their effect is bounded by intact negative feedback in a way that exogenous hormone is not, they depend on a pituitary that can still respond, and no head-to-head trial has established that they deliver comparable outcomes. "Works through the same axis" is not "works the same way".

Is one safer than the other? There is no comparative safety trial that answers this. The mechanistic argument for secretagogues is that preserved feedback limits how far the axis can be pushed, which plausibly limits the associated risks; the counter-argument is that recombinant GH's risks are at least documented and monitored, whereas most secretagogues have little or no long-term human safety data and are frequently obtained as unregulated research chemicals of unverified identity. Those are different kinds of uncertainty, not different amounts of the same one, and neither reduces to a ranking.

If secretagogues preserve pulsatility, isn't that automatically better? It is a real mechanistic difference and worth understanding, but "more physiological" describes a mechanism, not a result. Pattern of GH exposure has been shown to influence downstream signalling, largely in animal models. Establishing that the difference produces better outcomes in people requires trials comparing the two, and those trials have not been done in healthy adults. It should be held as a plausible reason the two might differ, not as a demonstrated advantage. It is also worth noting that not all secretagogues preserve pulsatility equally - long-acting analogues are specifically engineered to produce sustained elevation instead.

Why does an approved indication for one of these compounds not carry over? Because approval is granted for a defined use in a defined population on the basis of trials conducted in that population. Tesamorelin's approval rests on trials in people with HIV-associated lipodystrophy, and it establishes a benefit-risk balance for that condition. It says nothing about benefit-risk in a healthy adult, whose baseline physiology, expected benefit and risk tolerance are all different. "Approved for X" is a fact about X. Treating it as evidence for Y is the single most common error in how this category is marketed.

Related reading

• The GH axis and GHRH peptides - the underlying mechanism, and where each compound class sits in the chain. Read this first if the terminology on this page is unfamiliar
• What an IGF-1 level means - the marker both approaches are judged on, and why moving it is not the same as a result
• Sermorelin vs CJC-1295 vs tesamorelin - the head-to-head within the GHRH analogues, including half-life and status differences
• How the GH and testosterone axes differ - a comparison across two separate endocrine systems, rather than within one
• MK-677 - the orally active non-peptide secretagogue, its trial data, and why it never reached market
• The GH pulse and deep sleep - the largest natural GH pulse of the day, and what affects it
• GHRP-2, GHRP-6 and hexarelin - the first-generation secretagogues and why newer ones replaced them
• Growth hormone and cancer risk - what the observational data actually shows
• Testosterone vs GH peptides for muscle and recomposition - what each one actually changes

Part of The Complete Guide to Growth-Hormone Peptides.

Educational content, not medical advice and not a treatment claim. Recombinant human growth hormone is an approved prescription medicine for a narrow set of indications and is not approved for anti-ageing, athletic performance or body composition in healthy adults; in the United States its distribution for such purposes is restricted by federal statute. Of the secretagogues named here, only tesamorelin holds a treatment approval, limited to HIV-associated lipodystrophy, and macimorelin is approved only as a diagnostic agent; sermorelin's branded approval lapsed in 2008 and it exists as a compounded preparation; CJC-1295, ipamorelin, the GHRP series and MK-677 (ibutamoren) are not approved medicines anywhere and several are sold as research chemicals with no approved status and limited or absent long-term human safety data. Stimulating the GH/IGF-1 axis is contraindicated in active malignancy. Any use is investigational and requires physician supervision. Claims for the Malaysian market are subject to MAB requirements.

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore Tesamorelin.

References

• Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007;146(2):104–115. (Small changes in lean and fat mass without improvement in strength or function; significantly higher rates of adverse events including oedema, arthralgia, carpal tunnel syndrome and impaired fasting glucose.)
• Blackman MR, Sorkin JD, Münzer T, et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA. 2002;288(18):2282–2292.
• Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601–611. (Two-year randomised placebo-controlled trial of MK-677; GH and IGF-1 increased towards young-adult levels, fat-free mass increased, strength and function not significantly improved, fasting glucose increased and insulin sensitivity reduced.)
• Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor (tesamorelin) in patients with HIV. N Engl J Med. 2007;357(23):2359–2370. - with Falutz J, et al. Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311–322.
• Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805.
• Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561.
• Veldhuis JD, Roemmich JN, Richmond EJ, et al. Endocrine control of body composition in infancy, childhood, and puberty. Endocr Rev. 2005;26(1):114–146. (Deconvolution characterisation of pulsatile GH secretion and its relationship to sleep architecture.)
• Waxman DJ, O'Connor C. Growth hormone regulation of sex-dependent liver gene expression. Mol Endocrinol. 2006;20(11):2613–2629. (Pulsatile versus continuous GH exposure produces distinct intracellular signalling and hepatic gene-expression patterns; rodent model.)
• Molitch ME, Clemmons DR, Malozowski S, et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(6):1587–1609.
• United States federal restriction on distribution and possession of human growth hormone for uses other than treatment of a disease or recognised medical condition authorised by the FDA and pursuant to a valid prescription (21 U.S.C. § 333(e)).
• Somatropin product labelling - indications are product-specific and vary between approved somatropin preparations.